Categories Uncategorized

United Medical Equipment Business Solutions Network Inc. May Offer Response to US Prescription Drugs Price Crisis; Provides GoodRx Functionality within its Medication Management App

  • Americans pay more for prescription drugs than any other nation in the world; prices keep increasing
  • Patients pay about 14% of prescription drug costs out of pockets; around 20% report not being able to complete a prescribed course of medicine due to costs
  • UME’s committed to providing consumers better access to the healthcare they need; its Medication Management App features GoodRx in-built functionality enabling them to view discount prices and coupons

United Medical Equipment Business Solutions Network (“UME”) has developed the Medication Management App with twelve different functionalities within the convenience of one application, with the newest addition of GoodRX — a feature that allows users to save money on prescription drugs. Prescription drug spending in the US eclipse that in all other countries — on average $1,200 per person per year — mainly due to high prices of brand-name drugs, which have been increasing faster than the consumer price index (https://ibn.fm/4wdP7). 

Market exclusivity protected by monopoly rights and patents allows manufacturers to set high drug prices. The prices usually fall after the exclusivity period ends and generic drugs become available, but access to them may be postponed by numerous business and legal tactics. Another contributing factor to high medication spending is doctors prescribing more expensive choices when cheaper alternatives are available. Although high prices are often justified by the high cost of drug research and development, there is no evidence to support this. Instead, prescription drugs are often priced based on what the market will bear.

As patients pay about 14% of prescription drug costs out of their own pockets, many are not able to afford the medication bills. A survey found that 20% of US adults could not complete a prescribed course of medicine because of cost, compared to 10% in Germany, Canada, and Australia.

UME’s Medication Management App enables users to make quick, well-informed, and potentially lifesaving decision making on the go. The app features an integrated GoodRx function that allows users to view discount prices and coupons while managing medications all within the app. GoodRx, a company allowing users to compare drug prices and find coupons at over 60,000 pharmacies across the US, enables consumers to shop around for prescription drugs and lower their medication costs. 

Around 20 million people visit GoodRx every month, and over the past decade, the app has helped more than 18 million patients pay for a prescription medication they otherwise would not have been able to afford, saving them around $30 billion to date (https://ibn.fm/3Yfyo). 

With the help of the GoodRx in-built feature, the UME’s Medication Management App users can compare prices between pharmacies, access free coupons for their prescriptions, and show the coupon to the pharmacist when picking up the prescription — all without ever leaving the app. As US drug manufacturers remain unregulated, which means they can set any price they believe the market will bear for a given drug, the out-of-pocket costs for patients will likely continue to rise. UME strives to be the leading provider of high-quality, reliable, and transparent information and resources for consumers, helping them access the high-quality, affordable healthcare they need.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

New Photodynamic Therapy Offers Hope Against Brain Cancer

A planned preclinical study testing a light-activated therapy that helps to kill residual brain cancer cells after…

2 days ago

Novel Yeast Cell Platform Promises to Expedite the Development of Immunotherapies

Researchers have developed a technological platform that leverages yeast cells to test and understand new cancer treatments…

3 days ago

The Anti-Dilution Playbook: How Earth Science Tech Inc. (ETST) Rewrote the OTC Capital Structure Narrative

The company has issued zero common shares since October 2023, marking a decisive break from…

3 days ago

Improving the Odds: How LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective

LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell survival and treatment…

4 days ago

Policy Expert Offers Suggestions for Curbing US Health Care Costs

According to recent data, health expenditures in the U.S. reached $5.3 trillion in 2024. That figure equates…

5 days ago

Soligenix Inc. (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer

Although CTCL may progress slowly in its early stages, it remains a chronic and ultimately…

6 days ago